Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MDH2 | P40926 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10371822 | 0.89 | PARP10 (0.46) | SRD5A2MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL17440088 | 0.87 | RXRA (0.52) | RAB9AMEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL10895392 | 0.86 | MAPT (0.45) | SRD5A2GAARAB9AMEN1KMT2A | |
| SCHEMBL9741507 | 0.85 | RAB9A (0.51) | SRD5A2RAB9AMEN1KMT2ASRD5A1 | |
| SCHEMBL15275357 | 0.83 | PKM (0.45) | SRD5A2MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL15275361 | 0.82 | NPC1 (0.51) | GAARAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL2116326 | 0.80 | L3MBTL1 (0.54) | GAACYP2C9SMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL71120 | 0.79 | GSTP1 (0.44) | RAB9AMEN1KMT2ACYP2C9CYP1A2 | |
| SCHEMBL10897164 | 0.79 | L3MBTL1 (0.45) | SRD5A2GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL14124962 | 0.78 | NR1H4 (0.47) | GAARAB9AMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092083-A1 | VANCOMYCIN DERIVATIVES WITH SIDEROPHORE MODIFICATION AS NOVEL REPURPOSED ANTIBIOTICS TO COMBAT GRAM-NEGATIVE BACTERIAL INFECTION | RESEARCH TRIANGLE INSTITUTE (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4676533-A1 | VANCOMYCIN DERIVATIVES WITH SIDEROPHORE MODIFICATION AS NOVEL REPURPOSED ANTIBIOTICS TO COMBAT GRAM-NEGATIVE BACTERIAL INFECTION | Research Triangle Institute (US) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024191690-A1 | VANCOMYCIN DERIVATIVES WITH SIDEROPHORE MODIFICATION AS NOVEL REPURPOSED ANTIBIOTICS TO COMBAT GRAM-NEGATIVE BACTERIAL INFECTION | RESEARCH TRIANGLE INSTITUTE (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20220402873-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES | AUTOTAC INC. (KR) | 2022-12-22 | — | — | US | disclosed |
| US-20220402873-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES | AUTOTAC INC. (KR) | 2022-12-22 | — | — | US | disclosed |
| EP-4074709-A1 | MONOCYCLIC BETA-LACTAM COMPOUND AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2022-10-19 | — | — | EP | disclosed |
| WO-2021115444-A1 | MONOCYCLIC β-LACTAM COMPOUND AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| WO-2021054804-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES | 주식회사 오토텍바이오 | 2021-03-25 | — | — | WO | disclosed |
| US-8324198-B1 | Monocarbams | PFIZER INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324198-B1 | Monocarbams | PFIZER INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-0243924-B1 | 2-OXO-1-(SUBSTITUTED PHOSPHOROUS)AZETIDINES | E.R. Squibb & Sons, Inc. (US) | 1992-12-23 | — | — | EP | disclosed |
| EP-0336369-A1 | 3-Acylamino-1-[[[(substituted sulfonyl)amino]carbonyl]amino]2-azetidinones | E.R. Squibb & Sons, Inc. (US) | 1989-10-11 | — | — | EP | disclosed |
| US-4871841-A | 2-Oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines | E. R. SQUIBB & SONS, INC. (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0303286-A1 | 2-Oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines | E.R. Squibb & Sons, Inc. (US) | 1989-02-15 | — | — | EP | disclosed |
| US-4777252-A | 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines | E. R. SQUIBB & SONS, INC. (US) | 1988-10-11 | — | — | US | disclosed |
| US-4743685-A | 2-oxo-1-[[(substituted sulfonyl)amino]carbonyl]azetidines | E. R. SQUIBB & SONS, INC. (US) | 1988-05-10 | — | — | US | disclosed |
| US-4723002-A | 1-(substituted phosphorous)-azetidinone antibacterials | E. R. SQUIBB & SONS, INC. | 1988-02-02 | — | — | US | disclosed |
| EP-0243924-A2 | 2-Oxo-1-(substituted phosphorous)azetidines | E.R. Squibb & Sons, Inc. (US) | 1987-11-04 | — | — | EP | disclosed |
| US-4632985-A | 3-acylamino-2-oxo-1-azetidinesulfonic acids | E. R. SQUIBB & SONS, INC. (US) | 1986-12-30 | — | — | US | disclosed |
| EP-0204207-A1 | 3-acylamino-2-oxo-1-azetidinesulfonic acids | E.R. Squibb & Sons, Inc. (US) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092083-A1 | VANCOMYCIN DERIVATIVES WITH SIDEROPHORE MODIFICATION AS NOVEL REPURPOSED ANTIBIOTICS TO COMBAT GRAM-NEGATIVE BACTERIAL INFECTION | SLC11A2, SLC39A11, SLC39A3 | SRD5A2 519/4885GAA 3863/4885RAB9A 120/4885 |
| US-20220402873-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES | SQSTM1, ATG7, ATG13 | SRD5A2 4485/4885GAA 303/4885RAB9A 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.